감염병 체외진단 시장 : 제품별, 기술별, 병원체별, 용도별, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Infectious Diseases In-Vitro Diagnostics Market is projected to grow by USD 40.98 billion at a CAGR of 6.35% by 2032.

Infectious diseases in-vitro diagnostics (IVD) sit at the center of global health security, enabling rapid identification of respiratory viruses, antimicrobial-resistant organisms, sexually transmitted infections, tuberculosis, HIV, hepatitis, gastrointestinal pathogens, and emerging zoonotic threats. Demand is supported by the World Health Organization's continued focus on surveillance, the CDC's emphasis on diagnostic stewardship, and the persistent clinical need to distinguish bacterial, viral, fungal, and parasitic infections quickly and accurately.

The market is increasingly shaped by molecular diagnostics, immunoassays, syndromic panels, point-of-care testing, digital microbiology, and laboratory automation. Procurement decisions are moving beyond test sensitivity and specificity to include turnaround time, reimbursement alignment, workflow integration, quality controls, data interoperability, and capacity to support outbreak preparedness across centralized labs, hospitals, urgent care networks, and decentralized community settings.

Transformative Shifts in the Diagnostic Landscape

The infectious diseases IVD landscape is shifting from single-pathogen, centralized testing toward connected diagnostic ecosystems that combine high-throughput laboratory platforms with rapid near-patient testing. COVID-19 accelerated acceptance of molecular testing, self-collection, decentralized sampling, and public-health reporting infrastructure, creating durable expectations for faster access and scalable testing during seasonal surges.

Healthcare systems are also prioritizing antimicrobial resistance surveillance, sepsis diagnostics, tuberculosis testing, and multiplex respiratory panels as clinicians seek earlier targeted therapy. At the same time, regulatory scrutiny, supply-chain resilience, laboratory workforce shortages, and payer pressure are influencing product design. Manufacturers that can deliver clinically actionable results, automated workflows, cybersecurity-ready connectivity, and evidence of improved patient outcomes are better positioned in this evolving IVD market.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative force in infectious diseases diagnostics by improving assay development, image interpretation, epidemiological modeling, workflow triage, and result interpretation. AI-enabled algorithms can support digital pathology, Gram stain review, antimicrobial susceptibility prediction, syndromic decision support, and outbreak signal detection when validated against high-quality clinical datasets and governed by transparent quality systems.

The impact is strongest when AI is embedded into laboratory information systems, electronic health records, and surveillance networks rather than treated as a standalone tool. However, adoption depends on data representativeness, regulatory validation, explainability, cybersecurity, privacy safeguards, and clinician trust. Organizations that combine AI with rigorous clinical performance evidence can improve speed, consistency, and population-level infectious disease intelligence.

Key Regional Insights: Global IVD Adoption Patterns

Asia-Pacific is a high-priority region for infectious diseases IVD due to large populations, expanding hospital infrastructure, tuberculosis and hepatitis screening programs, and rising molecular testing capacity in China, India, Japan, South Korea, Australia, and ASEAN markets. North America remains a technology and reimbursement leader, supported by strong clinical laboratory networks, FDA oversight, CDC surveillance priorities, and sustained demand for respiratory, STI, sepsis, healthcare-associated infection, and antimicrobial resistance testing.

Europe benefits from harmonized quality expectations under the EU IVDR, strong public-health laboratories, and broad antimicrobial stewardship programs, while Latin America is expanding access through public procurement, private diagnostics chains, and infectious disease screening initiatives in Brazil and Mexico. The Middle East is investing in advanced hospital diagnostics and health-system modernization, particularly across GCC countries, while Africa's priorities center on affordable point-of-care testing, HIV, malaria, tuberculosis, hepatitis, neglected tropical diseases, and outbreak surveillance supported by national and international health programs.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are expanding infectious diseases IVD capacity through hospital modernization, dengue and tuberculosis testing, hepatitis screening, and stronger cross-border outbreak surveillance. The GCC is prioritizing premium hospital diagnostics, national screening initiatives, digital health integration, and laboratory automation as part of broader health transformation strategies. The European Union is reshaping supplier requirements through IVDR compliance, clinical evidence expectations, traceability, and post-market performance monitoring.

BRICS countries represent substantial diagnostic demand because of large patient populations, infectious disease burden, and growing domestic diagnostic manufacturing capabilities. G7 markets drive innovation, reimbursement evidence, laboratory quality standards, and advanced molecular adoption, while NATO-aligned health systems increasingly view diagnostics as part of biosecurity, preparedness, and resilient medical supply chains. Across these groups, successful IVD strategies align clinical utility with affordability, regulatory readiness, interoperability, and dependable supply.

Key Country Insights Across Major IVD Markets

The United States leads in advanced molecular platforms, multiplex respiratory testing, commercial laboratory scale, and rapid adoption of digital reporting, while Canada emphasizes quality-assured public health testing and equitable access across provinces. Mexico and Brazil are expanding infectious disease diagnostics through public programs, private laboratory networks, and screening initiatives for respiratory infections, HIV, hepatitis, tuberculosis, and vector-borne diseases. In Europe, the United Kingdom, Germany, France, Italy, and Spain combine mature hospital systems with antimicrobial stewardship priorities, sepsis management, and EU IVDR-aligned quality expectations, while Russia maintains demand for tuberculosis, respiratory, hepatitis, and hospital infection testing.

China is rapidly scaling domestic IVD innovation and hospital laboratory capacity, India is expanding affordable molecular and point-of-care testing for tuberculosis, hepatitis, HIV, and respiratory infections, and Japan prioritizes high-quality automated diagnostics for hospitals and aging-care settings. Australia and South Korea stand out for strong surveillance infrastructure, advanced hospital laboratories, antimicrobial resistance monitoring, and early adoption of digital and molecular diagnostic technologies.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize platforms that deliver clinically actionable results within the time window needed to influence treatment, isolation, and antimicrobial stewardship decisions. Product roadmaps should emphasize multiplex flexibility, sample-to-answer automation, connectivity with laboratory information systems, electronic health record compatibility, and evidence packages that demonstrate reduced length of stay, optimized antibiotic use, improved infection control, or stronger outbreak response.

Manufacturers should diversify supply chains for reagents, plastics, enzymes, controls, and instruments while building regulatory strategies tailored to FDA, EU IVDR, and high-priority emerging-market requirements. Commercial teams should segment customers by care setting, testing volume, reimbursement pathway, laboratory workforce capacity, and public-health need. Strategic partnerships with hospitals, reference laboratories, governments, and digital health providers can accelerate adoption and strengthen long-term market resilience.

Research Methodology and Evidence Framework

This executive summary is developed using a structured secondary-research approach grounded in publicly available, authoritative sources such as WHO, CDC, ECDC, FDA, OECD, World Bank, national health agencies, peer-reviewed literature, and regulatory guidance. The methodology evaluates disease burden, testing demand, regulatory dynamics, technology adoption, healthcare infrastructure, laboratory capacity, surveillance priorities, and procurement patterns across regions, groups, and key countries.

Insights are synthesized through triangulation of public-health priorities, laboratory workflow trends, reimbursement considerations, regulatory evidence requirements, and competitive technology signals. The analysis avoids unsupported claims and focuses on verifiable indicators, including surveillance needs, antimicrobial resistance priorities, molecular testing adoption, point-of-care expansion, quality-assurance requirements, and health-system investment patterns relevant to infectious diseases IVD decision-making.

Conclusion: Diagnostics as a Core Health Security Asset

Infectious diseases IVD is evolving from episodic testing into a strategic pillar of precision care, antimicrobial stewardship, infection prevention, and public-health preparedness. The most competitive organizations will combine reliable assay performance with faster workflows, digital connectivity, scalable manufacturing, resilient supply chains, and clear clinical utility.

As health systems face respiratory virus seasonality, antimicrobial resistance, endemic infections, healthcare-associated infections, and emerging pathogens, demand will favor diagnostics that support earlier decisions and stronger surveillance. Organizations that align innovation with regulatory evidence, affordability, interoperability, and regional healthcare priorities can support sustainable growth while improving patient outcomes and population health security.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Infectious Diseases In-Vitro Diagnostics Market, by Product

• 7.1. Instruments
  • 7.1.1. Automated Culture Systems
  • 7.1.2. Immunoassay Instruments
  • 7.1.3. PCR Instruments
• 7.2. Reagents & Kits
  • 7.2.1. Immunoassay Kits
  • 7.2.2. Microbial Culture Media
  • 7.2.3. PCR Reagents
• 7.3. Software & Services
  • 7.3.1. Consulting Services
  • 7.3.2. Data Management Software
  • 7.3.3. Maintenance & Support Services

8. Infectious Diseases In-Vitro Diagnostics Market, by Technology

• 8.1. Immunoassays
  • 8.1.1. Chemiluminescence Immunoassay
  • 8.1.2. Enzyme Linked Immunosorbent Assay
  • 8.1.3. Fluorescence Immunoassay
  • 8.1.4. Lateral Flow Assay
• 8.2. Microbiology Culture
• 8.3. Molecular Diagnostics
  • 8.3.1. Isothermal Amplification
  • 8.3.2. Next Generation Sequencing
  • 8.3.3. Polymerase Chain Reaction

9. Infectious Diseases In-Vitro Diagnostics Market, by Pathogen

• 9.1. Bacterial
  • 9.1.1. Enterobacteriaceae
  • 9.1.2. Mycobacterium Tuberculosis
  • 9.1.3. Staphylococcus Aureus
• 9.2. Fungal
• 9.3. Parasitic
• 9.4. Viral
  • 9.4.1. Hepatitis Virus
  • 9.4.2. Human Immunodeficiency Virus
  • 9.4.3. Influenza Virus

10. Infectious Diseases In-Vitro Diagnostics Market, by Application

• 10.1. Diagnosis
• 10.2. Epidemiological Surveillance
• 10.3. Monitoring
• 10.4. Screening

11. Infectious Diseases In-Vitro Diagnostics Market, by End User

• 11.1. Academic Research Institution
• 11.2. Clinic
• 11.3. Hospital
• 11.4. Laboratory

12. Infectious Diseases In-Vitro Diagnostics Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Infectious Diseases In-Vitro Diagnostics Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Infectious Diseases In-Vitro Diagnostics Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Abbott Laboratories
• 16.2. Becton, Dickinson and Company
• 16.3. Bio-Rad Laboratories, Inc.
• 16.4. bioMerieux SA
• 16.5. Danaher Corporation
• 16.6. DiaSorin S.p.A
• 16.7. Epitope Diagnostics, Inc.
• 16.8. F. Hoffmann La-Roche Ltd.
• 16.9. Grifols, S.A.
• 16.10. Hologic, Inc.
• 16.11. Illumina, Inc.
• 16.12. InBios International, Inc.
• 16.13. Koninklijke Philips N.V.
• 16.14. Merck KGaA
• 16.15. Meril Life Sciences Pvt. Ltd.
• 16.16. OraSure Technologies, Inc.
• 16.17. Qiagen N.V.
• 16.18. Quest Diagnostics
• 16.19. Quidel Corporation
• 16.20. Siemens Healthineers AG
• 16.21. Sysmex Corporation
• 16.22. Thermo Fisher Scientific Inc.
• 16.23. Trinity Biotech PLC
• 16.24. Vela Diagnostics